GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
Authors:
- Marika DębikMDMarika Dębik
- Łukasz SzydłowskiŁSŁukasz Szydłowski
- Klaudia ŻurowskaKŻKlaudia Żurowska
- Artur BednarskiABArtur Bednarski
- Aleksandra KrużelAKAleksandra Krużel
- Seweryn ZiajorSZSeweryn Ziajor
- Piotr SajdakPSPiotr Sajdak
- Justyna TomasikJTJustyna Tomasik
- Marcel StodolakMSMarcel Stodolak
- Kamil KłosKKKamil Kłos
Open Access
- 22 February 2024
- journal article
- research article
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 62, 217-239
Abstract
Introduction and purpose: Diabetes has emerged as a global lifestyle disease, with an alarming rise in cases, particularly of type 2 diabetes. In Poland, over 3 million people are diagnosed, and an estimated 4 million cases are expected by 2030. Effective treatment involves a multifaceted approach, including dietary intervention, physical activity, and pharmacological options. Incretins, such as glucagon-like peptide-1 (GLP-1), play a pivotal role in carbohydrate metabolism regulation, and GLP-1 analogs have become essential in managing type 2 diabetes. This paper explores the development and mechanisms of GLP-1 analogs, detailing their impact on insulin secretion, gastric emptying, and weight reduction. Description of the state knowledge: Various GLP-1 receptor agonists, including exenatide, liraglutide, dulaglutide, semaglutide, and the novel tirzepatide, are discussed. These drugs exhibit diverse pharmacokinetics, modes of administration, and effects on glucose metabolism and weight. Despite their efficacy, there is a concerning trend of off-label use, particularly for obesity treatment, leading to shortages for patients with valid prescriptions. This misuse is fueled by para-advertising on social media platforms, contributing to a surge in prescriptions and reimbursement costs. To address this, guidelines for GLP-1 analog use in obesity treatment are proposed, emphasizing the need for a stable drug supply and normalizing drug availability. Summary: In 2023, concerns intensified with reports of counterfeit GLP-1 analogs, prompting regulatory interventions. The paper concludes by underscoring the critical role GLP-1 analogs play in diabetes and obesity treatment, while emphasizing the importance of responsible prescription practices, guidelines adherence, and regulatory vigilance to ensure patient safety and mitigate the risks associated with misuse and counterfeit drugs.Keywords
This publication has 55 references indexed in Scilit:
- Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammationKidney International, 2023
- Incretin hormones and type 2 diabetesDiabetologia, 2023
- The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled TrialsReproductive Sciences, 2023
- The expanding incretin universe: from basic biology to clinical translationDiabetologia, 2023
- Nutrients handling after bariatric surgery, the role of gastrointestinal adaptationEating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2021
- Semaglutide: Review and Place in Therapy for Adults With Type 2 DiabetesCanadian Journal of Diabetes, 2019
- Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 DiabetesClinical Pharmacokinetics, 2018
- PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass SurgeryCell Reports, 2016
- Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration?Diabetologia, 2005
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987